Puruishunxiang Completes Series A Financing, with MedBio Capital Acting as Exclusive Financial Advisor

2025-03-18 08:01:00

Puruishunxiang Completes Series A Financing, with MedBio Capital Acting as Exclusive Financial Advisor, cover image

Recently, Puruishunxiang, a leading domestic supplier of minimally invasive surgical instrument products, successfully obtained a Series A investment of tens of millions of yuan from Yizhuang Guotou (亦庄国投), and MedBio Capital served as the financial advisor for this financing transaction.

The company has already launched a new financing round, and MedBio Capital continues to provide its services.

This collaboration will inject strong momentum into Puruishunxiang’s continued innovation and market expansion in the medical device field.

Exterior view of the Puruishunxiang office building

The Puruishunxiang team has been deeply engaged in the medical device industry for many years. Founder Zou Jianlong previously built 安和加利尔, the leading domestic ultrasonic scalpel brand, and successfully completed an M&A exit.

Building on years of technological accumulation and the translation of clinical results, the company has established five core technology platforms in trauma surgery, energy-based surgery, electronic endoscopy, high-value consumables and CDMO. Its product portfolio is extensive, covering ultrasonic aspiration scalpels, radiofrequency plasma, ultrasonic scalpel systems, urological surgical consumable series, endoscopic surgery systems and nerve conduits, among other products, and it has obtained more than 30 medical device registration certificates in China and abroad.

2024 was the company’s first year of commercialization. Multiple innovative products have already entered clinical use at a number of leading hospitals in China and have been well received by clinical experts.

The company has always been guided by clinical needs and has persisted in technological innovation, with product iteration keeping pace with advances in medicine. It has achieved notable results in solving clinical problems, and can not only provide stable and reliable products for established procedures, but also develop original instruments for advanced procedures. Its technical capabilities and product quality have been recognized by industry leaders.

As the investor in this round, Yizhuang Guotou has expressed a high degree of recognition of Puruishunxiang.

Puruishunxiang’s diverse technology platforms and product pipeline, as well as its strong performance in the process of domestic substitution, are highly aligned with the investment strategy of Yizhuang Guotou.

Through this investment, Yizhuang Guotou is expected to help Puruishunxiang further expand production scale and enhance R&D capabilities, accelerate the innovative development of domestically produced high-end minimally invasive surgical instruments, and promote the upgrading of the regional healthcare industry.

The MedBio Capital team said that Mr. Zou is a rare founder in China’s device sector who has successfully built a leading industry company and completed a well-executed M&A exit. Puruishunxiang has already built multiple technology platforms in the field of minimally invasive surgery, has many years of solid accumulation in localization and innovation translation, and its products have been widely recognized in clinical practice.

We believe that, with the support of the new shareholder, the company will make steady and sustained progress on the path of localization and innovation translation in minimally invasive surgery, and provide more and better solutions for clinical practice.

About MedBio Capital

MedBio Capital is a boutique investment bank focused on life sciences and healthcare, committed to serving as a capital and strategic partner to leading scientists and entrepreneurs. Its core team has worked in the healthcare industry for many years, covering key stages in R&D, clinical development and the market, and brings combined experience in investment, investment banking and consulting. Team members have collectively completed more than RMB 10 billion in financing transactions and have served more than a dozen leading listed healthcare companies.

This article was adapted from the MedBio Capital WeChat official account.